Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial

BACKGROUND: Pegmolesatide, a synthetic peptide-based erythropoietin (EPO) receptor agonist, is being evaluated as an alternative to epoetin alfa for treating anemia of chronic kidney disease (CKD) in Chinese dialysis patients. There is a critical need for a long-acting, cost-effective erythropoiesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ping, Jiang, Yan, Xu, Chunping, Zhou, Linghui, Zheng, Hongguang, Xie, Deqiong, Guo, Minghao, Huang, Xiangyang, Lu, Guoyuan, Jiang, Hongli, Qiu, Hongyu, Liu, Bicheng, Li, Shaomei, Chen, Qinkai, Xia, Yu'ou, Sun, Bengui, Yang, Xiao, Zhang, Shiying, Du, Shutong, Sun, Mindan, Chen, Menghua, Zhong, Aimin, Wang, Xiaoling, Zhao, Zhanzheng, Zhou, Hua, Li, Guisen, Ren, Yueqin, Luo, Qun, Yang, Aicheng, Luo, Ping, Tang, Shuifu, Xu, Chengyun, Wang, Qin, Wang, Xiaoxia, Yan, Tiekun, He, Wei, Qin, Shuguang, Zhang, Weili, Lv, Lu, Wang, Cheng, Liu, Hong, Li, Jing, Wu, Qiong, Pan, Chao, Li, Chuan, He, Liangliang, Chen, Jianghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632410/
https://www.ncbi.nlm.nih.gov/pubmed/37954906
http://dx.doi.org/10.1016/j.eclinm.2023.102273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632410/
https://www.ncbi.nlm.nih.gov/pubmed/37954906
http://dx.doi.org/10.1016/j.eclinm.2023.102273

Ejemplares similares